226 related articles for article (PubMed ID: 36695545)
1. Cerebrospinal fluid neurofilament light chains and CXCL13 as predictive factors for clinical course of multiple sclerosis.
Hradilek P; Revendova KZ; Horakova J; Bunganic R; Pelisek O; Zeman D; Hanzlikova P; Kusnierova P
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2023 Mar; 167(1):30-35. PubMed ID: 36695545
[TBL] [Abstract][Full Text] [Related]
2. Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study.
Rosenstein I; Axelsson M; Novakova L; Blennow K; Zetterberg H; Lycke J
Mult Scler; 2022 May; 28(6):872-884. PubMed ID: 34392718
[TBL] [Abstract][Full Text] [Related]
3. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
4. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis.
Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
Eur J Neurol; 2017 May; 24(5):703-712. PubMed ID: 28261960
[TBL] [Abstract][Full Text] [Related]
5. Prognostic relevance of the C-X-C motif chemokine ligand 13 and interleukin-8 in predicting the transition from clinically isolated syndrome to multiple sclerosis.
Klíčová K; Mareš J; Sobek O; Rous Z; Rous M; Raška M; Hartung HP
Eur J Neurosci; 2024 Jun; 59(11):2955-2966. PubMed ID: 38453679
[TBL] [Abstract][Full Text] [Related]
6. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
[TBL] [Abstract][Full Text] [Related]
7. Fatigue scores correlate with other self-assessment data, but not with clinical and biomarker parameters, in CIS and RRMS.
Håkansson I; Johansson L; Dahle C; Vrethem M; Ernerudh J
Mult Scler Relat Disord; 2019 Nov; 36():101424. PubMed ID: 31586802
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.
Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J
J Neurochem; 2017 Apr; 141(2):296-304. PubMed ID: 27787906
[TBL] [Abstract][Full Text] [Related]
9. NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS.
Novakova L; Axelsson M; Malmeström C; Zetterberg H; Blennow K; Svenningsson A; Lycke J
Mult Scler Relat Disord; 2020 Nov; 46():102463. PubMed ID: 32862040
[TBL] [Abstract][Full Text] [Related]
10. Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple sclerosis.
Rosenstein I; Rasch S; Axelsson M; Novakova L; Blennow K; Zetterberg H; Lycke J
Front Immunol; 2022; 13():967953. PubMed ID: 36032114
[TBL] [Abstract][Full Text] [Related]
11. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis.
Martínez MA; Olsson B; Bau L; Matas E; Cobo Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
Mult Scler; 2015 Apr; 21(5):550-61. PubMed ID: 25732842
[TBL] [Abstract][Full Text] [Related]
12. Demographic and disease-related factors impact on cerebrospinal fluid neurofilament light chain levels in multiple sclerosis.
Zondra Revendova K; Starvaggi Cucuzza C; Manouchehrinia A; Khademi M; Bar M; Leppert D; Sandberg E; Ouellette R; Granberg T; Piehl F
Brain Behav; 2023 Jan; 13(1):e2873. PubMed ID: 36573731
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T
PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354
[TBL] [Abstract][Full Text] [Related]
14. Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
Bridel C; Leurs CE; van Lierop ZYGJ; van Kempen ZLE; Dekker I; Twaalfhoven HAM; Moraal B; Barkhof F; Uitdehaag BMJ; Killestein J; Teunissen CE
Neurology; 2021 Nov; 97(19):e1898-e1905. PubMed ID: 34504023
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.
Sellebjerg F; Royen L; Soelberg Sørensen P; Oturai AB; Jensen PEH
Mult Scler; 2019 Oct; 25(11):1444-1451. PubMed ID: 30113249
[TBL] [Abstract][Full Text] [Related]
16. Neurofilament light chain in blood as a diagnostic and predictive biomarker for multiple sclerosis: A systematic review and meta-analysis.
Ning L; Wang B
PLoS One; 2022; 17(9):e0274565. PubMed ID: 36103562
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid neurofilament light chains predicts early disease-activity in Multiple Sclerosis.
Toscano S; Oteri V; Chisari CG; Finocchiaro C; Lo Fermo S; Valentino P; Bertolotto A; Zappia M; Patti F
Mult Scler Relat Disord; 2023 Dec; 80():105131. PubMed ID: 37951096
[TBL] [Abstract][Full Text] [Related]
18. The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS).
Brettschneider J; Czerwoniak A; Senel M; Fang L; Kassubek J; Pinkhardt E; Lauda F; Kapfer T; Jesse S; Lehmensiek V; Ludolph AC; Otto M; Tumani H
PLoS One; 2010 Aug; 5(8):e11986. PubMed ID: 20700489
[TBL] [Abstract][Full Text] [Related]
19. Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.
Schaller-Paule MA; Maiworm M; Schäfer JH; Friedauer L; Hattingen E; Wenger KJ; Weber F; Jakob J; Steffen F; Bittner S; Yalachkov Y; Foerch C
J Neurol; 2024 Jun; 271(6):3512-3526. PubMed ID: 38536455
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: Association with oligoclonal IgM bands and prediction of Multiple Sclerosis diagnosis.
Ferraro D; Galli V; Vitetta F; Simone AM; Bedin R; Del Giovane C; Morselli F; Filippini MM; Nichelli PF; Sola P
J Neuroimmunol; 2015 Jun; 283():64-9. PubMed ID: 26004159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
